Opportunities Preloader

Please Wait.....

Report

Phenylketonuria (PKU) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Industry Report I 2022-03-31 I 74 Pages I Global Markets Direct

Phenylketonuria (PKU) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Phenylketonuria (PKU) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Phenylketonuria (PKU) (Metabolic Disorders) pipeline landscape.

Phenylketonuria (also called PKU) is a rare inherited disorder that causes an amino acid called phenylalanine to build up in body. Symptoms include intellectual disability, psychiatric disorders, hyperactivity, skin rashes, poor bone strength and abnormally small head.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Phenylketonuria (PKU) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Phenylketonuria (PKU) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Phenylketonuria (PKU) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Phenylketonuria (PKU) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3, 11 and 8 respectively.

Phenylketonuria (PKU) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Phenylketonuria (PKU) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Phenylketonuria (PKU) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Phenylketonuria (PKU) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Phenylketonuria (PKU) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Phenylketonuria (PKU) (Metabolic Disorders)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Phenylketonuria (PKU) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Phenylketonuria (PKU) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Phenylketonuria (PKU) - Overview
Phenylketonuria (PKU) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Phenylketonuria (PKU) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Phenylketonuria (PKU) - Companies Involved in Therapeutics Development
Agios Pharmaceuticals Inc
American Gene Technologies International Inc
BioMarin Pharmaceutical Inc
Castle Creek Biosciences Inc
CommBio Therapeutics Co Ltd
Evox Therapeutics Ltd
Generation Bio Co
Hepatx Corp
Homology Medicines Inc
iECURE
Jnana Therapeutics Inc
Maze Therapeutics Inc
MipSalus ApS
Moderna Inc
Nestle Health Science
Peg-Bio BioPharma Co Ltd
Pluvia AS
Prosit Sole Biotechnology (Beijing) Co Ltd
PTC Therapeutics Inc
Relief Therapeutics Holding AG
SOM Biotech SL
Synlogic Inc
Ultragenyx Pharmaceutical Inc
Vera Therapeutics Inc
Phenylketonuria (PKU) - Drug Profiles
AGT-324 - Drug Profile
Product Description
Mechanism Of Action
History of Events
APROD-031 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CDX-6114 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for Phenylketonuria - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target Phenylalanine Hydroxylase for Phenylketonuria - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene-Modified Cell Therapy to Activate PAH for Phenylketonuria - Drug Profile
Product Description
Mechanism Of Action
HMI-103 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HX-003 - Drug Profile
Product Description
Mechanism Of Action
JNT-517 - Drug Profile
Product Description
Mechanism Of Action
mRNA-3283 - Drug Profile
Product Description
Mechanism Of Action
Oligonucleotides to Activate PAH for Phenylketonuria - Drug Profile
Product Description
Mechanism Of Action
History of Events
PAH - Drug Profile
Product Description
Mechanism Of Action
pegvaliase - Drug Profile
Product Description
Mechanism Of Action
History of Events
Phelimin - Drug Profile
Product Description
Mechanism Of Action
History of Events
Phenylketonuria - Drug Profile
Product Description
Mechanism Of Action
PJ-008 - Drug Profile
Product Description
Mechanism Of Action
PKU - Drug Profile
Product Description
Mechanism Of Action
PSP-007 - Drug Profile
Product Description
Mechanism Of Action
sepiapterin - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule for Phenylketonuria - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Activate Phenylalanine Hydroxylase for Phenylketonuria - Drug Profile
Product Description
Mechanism Of Action
SOM-1311 - Drug Profile
Product Description
Mechanism Of Action
SYNB-1618 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SYNB-1934 - Drug Profile
Product Description
Mechanism Of Action
History of Events
UX-501 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Phenylketonuria (PKU) - Dormant Projects
Phenylketonuria (PKU) - Discontinued Products
Phenylketonuria (PKU) - Product Development Milestones
Featured News & Press Releases
Feb 23, 2022: Jnana Therapeutics to advance JNT-517 as development candidate and potential first-in-class oral treatment for PKU
Nov 22, 2021: Synlogic presents data demonstrating reductions in plasma phenylalanine levels in patients with phenylketonuria treated with SYNB1934
Nov 22, 2021: Synlogic presents data demonstrating reductions in plasma phenylalanine levels in patients with phenylketonuria treated with SYNB1618
Nov 10, 2021: Synlogic announces presentation of data on SYNB1934 at 14th International Congress of Inborn Errors of Metabolism Meeting
Nov 10, 2021: Synlogic announces presentation of data on SYNB1618 at 14th International Congress of Inborn Errors of Metabolism Meeting
Oct 28, 2021: Synlogic announces Nature Communications publication highlighting use of synthetic biotic platform to optimize therapies for phenylketonuria
Oct 12, 2021: Homology Medicines announces world's first gene editing clinical trial for PKU
Sep 11, 2021: Synlogic presents at Global PKU Patient Meeting
Jul 22, 2021: Synlogic publishes papers in Nature journals demonstrating proof-of-mechanism and potential of synthetic biotic platform for the treatment of phenylketonuria (PKU)
Jul 15, 2021: Synlogic provides update on SYNB1618 , a next-generation strain for the treatment of Phenylketonuria (PKU)
Jul 15, 2021: Synlogic announces initiation of phase 1 study of SYNB1934, a next-generation strain for the treatment of Phenylketonuria (PKU)
Jun 15, 2021: Synlogic presents additional preclinical data on therapeutic candidate SYNB1934 for Phenylketonuria (PKU) at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
Apr 13, 2021: Synlogic presents data demonstrating activity of a solid oral formulation of SYNB1618 at American College of Medical Genetics (ACMG) annual meeting
Oct 07, 2020: BioMarin, pioneer in rare disease treatments for Phenylketonuria (PKU), receives FDA approval of label expansion to allow maximum dose of 60 mg for Palynziq (pegvaliase-pqpz) injection for treatment of adults with PKU
Mar 26, 2020: FDA grants Orphan Drug Designation to APR-OD031 for the treatment of phenylketonuria
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Phenylketonuria (PKU), 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Phenylketonuria (PKU) - Pipeline by Agios Pharmaceuticals Inc, 2022
Phenylketonuria (PKU) - Pipeline by American Gene Technologies International Inc, 2022
Phenylketonuria (PKU) - Pipeline by BioMarin Pharmaceutical Inc, 2022
Phenylketonuria (PKU) - Pipeline by Castle Creek Biosciences Inc, 2022
Phenylketonuria (PKU) - Pipeline by CommBio Therapeutics Co Ltd, 2022
Phenylketonuria (PKU) - Pipeline by Evox Therapeutics Ltd, 2022
Phenylketonuria (PKU) - Pipeline by Generation Bio Co, 2022
Phenylketonuria (PKU) - Pipeline by Hepatx Corp, 2022
Phenylketonuria (PKU) - Pipeline by Homology Medicines Inc, 2022
Phenylketonuria (PKU) - Pipeline by iECURE, 2022
Phenylketonuria (PKU) - Pipeline by Jnana Therapeutics Inc, 2022
Phenylketonuria (PKU) - Pipeline by Maze Therapeutics Inc, 2022
Phenylketonuria (PKU) - Pipeline by MipSalus ApS, 2022
Phenylketonuria (PKU) - Pipeline by Moderna Inc, 2022
Phenylketonuria (PKU) - Pipeline by Nestle Health Science, 2022
Phenylketonuria (PKU) - Pipeline by Peg-Bio BioPharma Co Ltd, 2022
Phenylketonuria (PKU) - Pipeline by Pluvia AS, 2022
Phenylketonuria (PKU) - Pipeline by Prosit Sole Biotechnology (Beijing) Co Ltd, 2022
Phenylketonuria (PKU) - Pipeline by PTC Therapeutics Inc, 2022
Phenylketonuria (PKU) - Pipeline by Relief Therapeutics Holding AG, 2022
Phenylketonuria (PKU) - Pipeline by SOM Biotech SL, 2022
Phenylketonuria (PKU) - Pipeline by Synlogic Inc, 2022
Phenylketonuria (PKU) - Pipeline by Ultragenyx Pharmaceutical Inc, 2022
Phenylketonuria (PKU) - Pipeline by Vera Therapeutics Inc, 2022
Phenylketonuria (PKU) - Dormant Projects, 2022
Phenylketonuria (PKU) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Phenylketonuria (PKU), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $2000.00
  • $4000.00
  • $6000.00
  • ADD TO BASKET
  • BUY NOW